


Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA

FDA Approves Subcutaneous Tocilizumab for Ages 2–17

Tocilizumab Promising for sJIA

• By Jason Liebowitz, MD
• By Carina Stanton
• By Kathy Holliman
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.